SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant /X/
Filed by a Party other than the Registrant / /
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted
by Rule 14a-6(e)(2))
/X/ Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material under Rule 14a-12
ISIS PHARMACEUTICALS, INC.
-----------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
-----------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment of Filing Fee (Check the appropriate box)
/X/ No fee required.
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(4)
and 0-11.
1. Title of each class of securities to which transaction
applies:
----------------------------------------------------------
2. Aggregate number of securities to which transaction
applies:
----------------------------------------------------------
3. Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (Set forth the
amount on which the filing fee is calculated and state how
it was determined):
----------------------------------------------------------
4. Proposed maximum aggregate value of transaction:
----------------------------------------------------------
5. Total fee paid:
----------------------------------------------------------
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by
Exchange Act Rule 0-11(a)(2) and identify the filing for which
the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the Form or
Schedule and the date of its filing.
1. Amount Previously Paid:
----------------------------------------------------------
2. Form, Schedule or Registration Statement No.:
----------------------------------------------------------
3. Filing Party:
----------------------------------------------------------
4. Date Filed:
----------------------------------------------------------
ISIS PHARMACEUTICALS, INC.
2292 FARADAY AVENUE
CARLSBAD, CA 92008
------------------------
NOTICE OF
2001 ANNUAL MEETING OF STOCKHOLDERS
AND PROXY STATEMENT
---------------------
Dear Stockholders,
I am pleased to invite you to Isis Pharmaceuticals' 2001 Annual Meeting of
Stockholders. We will host the meeting at our offices in Carlsbad, California on
Friday, April 6 at 2:30 P.M. In addition to covering the formal items on the
agenda, we will review the major developments of the past year and answer your
questions.
This booklet includes the agenda for this year's Annual Meeting and the
Proxy Statement. The Proxy Statement explains the matters we will discuss in the
meeting, and provides general information about Isis Pharmaceuticals.
Your vote is very important. Whether or not you plan to attend the meeting,
please complete, date, sign and return the enclosed proxy as soon as possible to
ensure your representation at the meeting. We have provided a postage-paid
envelope for your convenience. If you plan to attend the meeting and prefer to
vote in person, you may still do so even if you have already returned your
proxy.
If you are a stockholder of record (that is, if your stock is registered
with us in your own name), you may vote by telephone, or electronically through
the Internet, by following the instructions included with your proxy card. If
your shares are registered in the name of a broker or other nominee, your
nominee may be participating in a program provided through ADP Investor
Communication Services that allows you to vote by phone or the Internet. If so,
the voting form your nominee sends you will provide telephone and Internet
instructions.
PLEASE NOTE, HOWEVER, THAT IF A BROKER, BANK OR OTHER NOMINEE HOLDS YOUR
SHARES OF RECORD AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN A PROXY
ISSUED IN YOUR NAME FROM THE BROKER, BANK OR NOMINEE.
We look forward to seeing you at the meeting.
Sincerely,
/s/ B. Lynne Parshall
SECRETARY
ISIS PHARMACEUTICALS, INC.
2292 FARADAY AVENUE
CARLSBAD, CA 92008
------------------------
NOTICE OF 2001 ANNUAL MEETING OF STOCKHOLDERS
---------------------
DATE: Friday, April 6
TIME: 2:30 P.M.
PLACE: Isis Pharmaceuticals
2292 Faraday Avenue
Carlsbad, CA 92008
Dear Stockholders,
At our 2001 Annual Meeting, we will ask you to:
- Elect two Directors to serve for a three-year term;
- Approve an amendment to our Restated Certificate of Incorporation to
increase the authorized number of shares of Common Stock from 50,000,000
to 100,000,000 shares;
- Ratify the selection of Ernst & Young LLP as independent auditors for
2001; and
- Transact any other business that may properly be presented at the Annual
Meeting.
The foregoing items of business are more fully described in the enclosed
Proxy Statement.
If you were an Isis stockholder of record at the close of business on
February 15, 2001 you may vote at the Annual Meeting.
By order of the Board of Directors,
/s/ B. Lynne Parshall
SECRETARY
Carlsbad, California
March 6, 2001
ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE MEETING IN PERSON. WHETHER
OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN
THE ENCLOSED PROXY AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR
REPRESENTATION AT THE MEETING. A RETURN ENVELOPE (WHICH IS POSTAGE PREPAID IF
MAILED IN THE UNITED STATES) IS ENCLOSED FOR THAT PURPOSE. ALTERNATIVELY, YOU
MAY VOTE BY PHONE OR INTERNET BY FOLLOWING THE INSTRUCTIONS INCLUDED IN THIS
PROXY STATEMENT AND WITH YOUR PROXY CARD. EVEN IF YOU HAVE GIVEN YOUR PROXY, YOU
MAY STILL VOTE IN PERSON IF YOU ATTEND THE MEETING. PLEASE NOTE, HOWEVER, THAT
IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU
WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN FROM THE RECORD HOLDER A PROXY
ISSUED IN YOUR NAME.
ISIS PHARMACEUTICALS, INC.
2292 FARADAY AVENUE
CARLSBAD, CA 92008
------------------------
PROXY STATEMENT
INFORMATION ABOUT THE 2001 ANNUAL MEETING AND VOTING
---------------------
GENERAL
The enclosed proxy card has been sent to you by the Board of Directors of
Isis Pharmaceuticals, Inc., a Delaware corporation, for use at the 2001 Annual
Meeting of Stockholders to be held on Friday, April 6, 2001, at 2:30 P.M. local
time, or at any adjournment or postponement thereof, for the purposes stated
herein. The Annual Meeting will be held at 2292 Faraday Avenue, Carlsbad,
California. This Proxy Statement summarizes the information you will need to
know to vote in an informed manner.
VOTING RIGHTS AND OUTSTANDING SHARES
We will begin mailing this Proxy Statement and accompanying proxy card on or
about March 6, 2001 to all stockholders who are entitled to vote. Only
stockholders who owned our Common Stock at the close of business on
February 15, 2001 are entitled to vote at the Annual Meeting. On this record
date, we had 40,156,890 shares of our Common Stock outstanding.
Each share of our Common Stock that you own entitles you to one vote. The
proxy card indicates the number of shares of our Common Stock that you own. The
inspector of election will separately tabulate affirmative and negative votes,
abstentions and broker non-votes. Abstentions will count as a cast vote that has
the same effect as a negative vote. The inspector of election will count broker
non-votes towards a quorum. Except for Proposal 2, broker non-votes will not
count towards whether the stockholders have approved a proposal. With respect to
Proposal 2, abstentions and broker non-votes will have the same effect as
negative votes.
You may vote in one of three ways:
- Attend the 2001 Annual Meeting and vote in person;
- Complete, sign, date and return the enclosed proxy card; or
- Vote by telephone or the Internet by following the instructions included
with your proxy card.
SOLICITATION
We will bear the entire cost of solicitation of proxies, including
preparation, assembly, printing and mailing of this Proxy Statement, the proxy
card and any additional information furnished to stockholders. Copies of
solicitation materials will be furnished to banks, brokerage houses, fiduciaries
and custodians holding in their names shares of our Common Stock beneficially
owned by others to forward to such beneficial owners. We may reimburse persons
representing beneficial owners of Common Stock for their costs of forwarding
solicitation materials to such beneficial owners. Original solicitation of
proxies by mail may be supplemented by telephone, telegram or personal
solicitation by directors, officers or other employees of Isis or, at our
request, Georgeson Shareholder Communications Inc., a professional proxy
solicitation firm. No additional compensation will be paid to directors,
officers or other employees for such services, but Georgeson Shareholder
Communications Inc. will be paid its customary fee, estimated to be about
$10,000, if it renders solicitation services.
GENERAL INFORMATION FOR ALL SHARES VOTED VIA THE INTERNET OR BY TELEPHONE
Votes submitted via the Internet or by telephone must be received by 12:00
midnight, Eastern Daylight Time, on April 5, 2001. Submitting your proxy via the
Internet or by telephone will not affect your right to vote in person should you
decide to attend the Annual Meeting.
FOR SHARES REGISTERED IN YOUR NAME
If you are a stockholder of record, you may go to http://www.voteproxy.com
to vote your shares by means of the Internet. The votes represented by such
proxy will be generated on the computer screen and you will be prompted to
submit or revise your votes as desired. If you are using a touch-tone telephone
you may also vote your shares by calling 1-800-PROXIES (1-800-776-9437) and
following the recorded instructions. You will be required to provide the control
number contained on your proxy card when you vote either by telephone or the
Internet, so please have it available at the time you are voting.
FOR SHARES REGISTERED IN THE NAME OF A BROKER OR BANK
Most beneficial owners whose stock is held in street name receive
instructions for voting their shares from their bank, broker or other agent,
rather than our proxy card.
A number of brokers and banks are participating in a program provided
through ADP Investor Communication Services that allows proxies to vote shares
to be granted by means of the telephone and Internet. If your shares are held in
an account with a broker or bank participating in the ADP Investor Communication
Services program, you may vote your shares telephonically by calling the
telephone number shown on the instruction form received from your broker or
bank, or via the Internet at ADP Investor Communication Services' web site at
http://www.proxyvote.com.
REVOCABILITY OF PROXIES
Once you have submitted your proxy by mail, Internet or telephone, you may
revoke it at any time before we exercise it. You may revoke your proxy in any
one of three ways:
- You may send in by mail another proxy marked with a later date;
- You may notify our Secretary in writing that you wish to revoke your proxy
before the Annual Meeting takes place; or
- You may vote in person at the Annual Meeting. ATTENDANCE at the meeting
WILL NOT, by itself, revoke a proxy.
STOCKHOLDER PROPOSALS
If you have a proposal or director nomination that you would like to be
included in our proxy statement and form of proxy for, or to be presented at,
the 2002 Annual Meeting of Stockholders, you must send the proposal to Isis by
no later than November 6, 2001. Stockholders wishing to submit proposals or
director nominations that are not to be included in such proxy statement and
proxy must do so no earlier than the close of business on December 7, 2001 and
no later than the close of business on January 6, 2002. Stockholders are also
advised to review our Bylaws, which contain additional requirements with respect
to advance notice of stockholder proposals and director nominations.
PROPOSAL 1
ELECTION OF DIRECTORS
INFORMATION ABOUT OUR BOARD OF DIRECTORS
The Board is divided into three classes, each consisting as nearly as
possible of one third of the total number of directors. Presently, the Board has
six members, each class consisting of two directors.
2
Each class serves a three-year term, and we hold elections each year at the
Annual Meeting to elect the directors whose terms have expired.
During the course of a term, the Board may elect a new director to fill any
vacant spot, including a vacancy caused by an increase in the size of the Board.
The new director will finish out the term of the director he or she replaced.
One Board member, B. Lynne Parshall, was elected in September 2000. Two Board
members, Larry Soll and Alan C. Mendelson, resigned in July 2000 and
January 2001, respectively.
INFORMATION ABOUT THE 2001 ELECTIONS
The Board has nominated two directors for election at the 2001 Annual
Meeting. Each of the nominees currently serves as one of our directors. If
re-elected, each will serve until the 2004 annual meeting or until his successor
is elected and has qualified.
Our stockholders elect directors by a plurality of the votes of the shares
present in person or represented by proxy at the meeting and entitled to vote in
the election of directors. Shares represented by executed proxies will be voted
for the election of the nominees listed below, unless authority to vote in favor
of the nominees is withheld. Each person nominated for election has agreed to
serve if elected, and we have no reason to believe that any nominee will be
unable to serve. However, if any nominee cannot serve, your proxy may vote for
another nominee proposed by the Board, or the Board may reduce the number of
directors.
We provide below a short biographical description of each of the nominees
and of each director whose term of office will continue after the Annual
Meeting.
BIOGRAPHIES OF NOMINEES FOR ELECTION FOR A THREE-YEAR TERM EXPIRING AT THE 2004
ANNUAL MEETING
STANLEY T. CROOKE, M.D., Ph.D., age 56, was a founder of Isis and has been
Chief Executive Officer and a director since January 1989. He served as our
President from January 1989 to May 1994, and was elected Chairman of the Board
in February 1991. SmithKline Beckman Corporation, a pharmaceutical company,
employed Dr. Crooke from 1980 until January of 1989, where his titles included
President of Research and Development of SmithKline and French Laboratories.
Dr. Crooke is Chairman of the Board of Idun Pharmaceuticals, Inc., a
pharmaceutical company. He also serves as a director of Valentis, Inc., SYNSORB
Biotech Inc., and EPIX Medical, Inc. He is also an adjunct professor of
pharmacology at the Baylor College of Medicine and the University of California,
San Diego.
MARK B. SKALETSKY, age 52, has served as a director of Isis since
January 1989. From May 1993 to January 2001, Mr. Skaletsky served as President
and Chief Executive Officer of GelTex Pharmaceuticals, Inc., a biopharmaceutical
company. From 1989 to 1993, Mr. Skaletsky was Chairman of Enzytech, Inc., a
biopharmaceutical company, and Chief Executive Officer of Enzytech from 1988 to
1993. From 1998 to present, Mr. Skaletsky has been a director of Microcide
Pharmaceuticals, Inc., a biotechnology company, and from August 2000 to present,
he has been a director of ImmunoGen, Inc., a biotechnology company. He is also
currently Chairman of the Biotechnology Industry Organization. In addition,
Mr. Skaletsky is a member of the Board of Trustees of Bentley College located in
Waltham, MA.
THE BOARD RECOMMENDS THAT YOU VOTE IN FAVOR OF THE ELECTION OF EACH OF THE ABOVE
NOMINEES
BIOGRAPHIES OF BOARD MEMBERS CONTINUING UNTIL THE 2002 ANNUAL MEETING
B. LYNNE PARSHALL, age 46, has served as a director of Isis since
September 2000. She is Executive Vice President and Chief Financial Officer of
Isis and has been with Isis since 1991. Prior to joining Isis, Ms. Parshall was
a Partner with the law firm of Cooley Godward LLP. Ms. Parshall is on the Board
3
of Visitors at Stanford University Law School. Ms. Parshall is also a member of
the Licensing Executives Society and a member of the American, California and
San Diego bar associations.
JOSEPH H. WENDER, age 56, has served as a director of Isis since
January 1994. Mr. Wender is currently Senior Director of the Financial
Institutions Group at Goldman, Sachs & Co., an investment banking firm. He
joined Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in
1982 and a Limited Partner in 1992. He is also a director of First Coastal
Bancshares, a bank holding company, and Event 411, an Internet event planning
company.
BIOGRAPHIES OF BOARD MEMBERS CONTINUING UNTIL THE 2003 ANNUAL MEETING
WILLIAM R. MILLER, age 72, has served as a director of Isis since
March 1991. In January 1991, he retired as Vice Chairman of the Board of
Directors of Bristol-Myers Squibb Company, a position he had held since 1985. He
is Chairman of the Board of Trustees of the Cold Spring Harbor Laboratory.
Mr. Miller is also Chairman of the Board of Vion Pharmaceuticals, Inc., a
biopharmaceutical company. He is a director of ImClone Systems, Inc. and
Transkaryotic Therapies, Inc., both biopharmaceutical companies, and Westvaco
Corporation, a paper/packaging/specialty chemical manufacturer.
CHRISTOPHER F.O. GABRIELI, age 41, has served as a director of Isis since
May 1994. Mr. Gabrieli was a founder of Isis and served as a director from
January 1989 to May 1992. He is currently a manager of the general partners of
Bessemer Venture Partners II L.P., Bessemer Venture Partners III L.P., Bessemer
Venture Partners IV L.P. and related venture capital partnerships, where he has
worked since 1986. He is Chairman of the Board of EPIX Medical, Inc.
THE BOARD OF DIRECTOR COMMITTEES AND MEETINGS
The Board of Directors met six times in 2000, including four regularly
scheduled meetings, one special meeting and one special telephone meeting, and
acted by unanimous written consent five times. The Board of Directors also has
Audit, Compensation and Nominating committees. During 2000, all directors
attended 100% of the meetings of the Board and the committees on which they
served.
The Audit Committee is currently comprised of three directors, Mr. Wender
(Chairman), Mr. Gabrieli and Mr. Skaletsky. All members of our Audit Committee
are not officers of Isis and are independent directors under currently
applicable rules. Mr. Mendelson, an independent director who resigned from the
Board in January 2001, served as Chairman of the Audit Committee during 2000.
The Audit Committee has adopted a formal written Audit Committee Charter, which
was filed as an appendix to our 2000 Proxy Statement. The Audit Committee met
eight times in 2000. The Audit Committee:
- Reviews the annual and quarterly financial statements and oversees the
annual and quarterly financial reporting processes;
- Selects our independent auditors;
- Oversees the independence of our independent auditors;
- Evaluates our independent auditor's performance; and
- Receives and considers our independent auditor's comments as to controls,
adequacy of staff and management performance and procedures in connection
with audit and financial controls.
The Compensation Committee is comprised of Mr. Skaletsky (Chairman),
Mr. Miller and Mr. Wender, all of whom are non-employee directors of Isis. The
committee met two times in 2000 and acted by unanimous written consent twenty
times. The Compensation Committee:
- Makes recommendations concerning executive salaries and incentive
compensation;
4
- Awards stock options, bonus stock and rights to purchase restricted stock
under our 1989 Stock Option Plan and 2000 Broad-Based Equity Incentive
Plan;
- Administers our 1989 Stock Option Plan and 2000 Employee Stock Purchase
Plan; and
- Determines executive compensation levels and performs other functions
regarding compensation as the Board requests.
The Nominating Committee currently consists of two non-employee directors:
Mr. Gabrieli (Chairman) and Mr. Wender. In 2000, the Nominating Committee was
comprised of two non-employee directors, Mr. Mendelson and Dr. Soll, both of
whom were non-employee directors and have resigned from the Board. The committee
did not meet in 2000. The Nominating Committee:
- Interviews, evaluates, nominates and recommends individuals for membership
on our Board of Directors and its committees; and
- Considers nominees whom our stockholders may recommend.
In the event a stockholder would like to request the nomination of a
director at a meeting, the stockholder must submit written information which
provides:
- the name, age, business address and residence address of the proposed
nominee;
- the principal occupation or employment of such proposed nominee;
- the class and number of shares of Isis beneficially owned by such proposed
nominee; and
- a description of all arrangements or understandings between the
stockholder and each proposed nominee and any other person or persons who
are to be nominated by the stockholder.
PROPOSAL 2
APPROVAL OF INCREASE IN NUMBER OF AUTHORIZED SHARES OF COMMON STOCK
The Board of Directors has adopted, subject to stockholder approval, an
amendment to Isis' Restated Certificate of Incorporation to increase the
authorized number of shares of our Common Stock from 50,000,000 shares to
100,000,000 shares.
The additional Common Stock to be authorized by adoption of the amendment
would have rights identical to our currently outstanding Common Stock. Adoption
of the proposed amendment and issuance of the Common Stock would not affect the
rights of the holders of our Common Stock, Series A Preferred Stock or Series B
Preferred Stock, except for effects incidental to increasing the number of
shares of our Common Stock outstanding, such as dilution of the earnings per
share and voting rights of current holders of our Common Stock. If the amendment
is adopted, it will become effective upon filing of a Certificate of Amendment
of our Restated Certificate of Incorporation with the Secretary of State of the
State of Delaware. The complete text of the Certificate of Amendment to the
Restated Certificate that would be filed with the Secretary of State of the
State of Delaware is set forth in Exhibit A to this Proxy Statement. However,
the text of the Certificate of Amendment is subject to revision to include such
changes as may be required by the Secretary of State of the State of Delaware
and as the Board deems necessary and advisable to effect the proposed amendment
of our Restated Certificate of Incorporation.
5
In addition to the 40,119,564 shares of Common Stock outstanding at
January 12, 2001, we have reserved 2,634,463 shares of Common Stock for possible
issuance under a Form S-3 shelf registration statement currently on file with
the Securities and Exchange Commission (the "SEC"). Also as of January 12, 2001,
there were 7,533,560 shares of Common Stock issuable upon exercise of
outstanding options granted under our stock option plans and 3,364,012 shares of
Common Stock subject to future issuance under our equity plans. Isis has also
issued warrants and convertible debt which, on January 12, 2001, would have been
exercisable and convertible into an aggregate of 4,443,500 shares of Common
Stock. In addition, we have outstanding 120,150 shares of Series A Preferred
Stock and 12,015 shares of Series B Preferred Stock which is convertible into
Common Stock on March 31, 2002 and June 30, 2002, respectively. The Preferred
Stock converts into Common Stock at a premium to market at the time of
conversion. If our Preferred Stock were convertible on January 12, 2001, it
would convert into an aggregate of 1,984,345 shares of Common Stock on such
date.
Although at present the Board of Directors has no other plans to issue the
additional shares of Common Stock other than in the ordinary course of business
to employees and directors under our stock option and other equity plans, it
desires to have the shares available to provide Isis additional flexibility for
business and financial purposes in the future. The additional shares may be
used, without further stockholder approval, for various purposes including,
without limitation, raising capital, providing equity incentives to employees,
directors or consultants, establishing strategic relationships with other
companies and expanding our business or product lines through the acquisition of
other businesses or products.
Isis could also use the additional shares of Common Stock that would become
available for issuance if this proposal were adopted to oppose a hostile
takeover attempt or delay or prevent changes in control or management of Isis.
For example, without further stockholder approval, the Board could strategically
sell shares of Common Stock in a private transaction to purchasers who would
oppose a takeover or favor the current Board. Although this proposal to increase
the authorized Common Stock has been prompted by business and financial
considerations and not by the threat of any hostile takeover attempt, nor is the
Board currently aware of any such attempts directed at Isis, nevertheless,
stockholders should be aware that approval of this proposal could facilitate
future efforts by us to deter or prevent changes in control of Isis, including
transactions in which the stockholders might otherwise receive a premium for
their shares over then current market prices.
The affirmative vote of the holders of a majority of the outstanding shares
of the Common Stock on the record date will be required to approve this
amendment to the our Restated Certificate of Incorporation. As a result,
abstentions and broker non-votes will have the same effect as negative votes.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 2
PROPOSAL 3
RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS
The Board of Directors has selected Ernst & Young LLP as our independent
auditors for the fiscal year ending December 31, 2001, and has requested
management to ask for stockholder ratification at the Annual Meeting. Ernst &
Young LLP has audited our financial statements since we were founded in 1989.
Representatives of Ernst & Young LLP will be at the 2001 Annual Meeting to
answer any questions and make a statement should they choose to do so.
Although our Bylaws do not require stockholders to approve our independent
auditors, the Board would like to hear the stockholders' opinion as a matter of
good corporate practice. If the stockholders vote against Ernst & Young LLP, the
Board will reconsider whether or not to keep the firm. However, even if the
stockholders ratify the selection, the Board may choose to appoint a different
independent
6
accounting firm at any time during the year if it believes that a change would
be in the best interests of Isis and its stockholders.
To ratify the selection of Ernst & Young LLP, the holders of a majority of
shares present in person or represented by proxy and entitled to vote at the
2001 Annual Meeting must vote in favor of Proposal 3.
During the fiscal year ended December 31, 2000, the aggregate fees billed by
Ernst & Young LLP for the audit of our financial statements for such fiscal year
and for the reviews of our interim financial statements was $55,450.
During the fiscal year ended December 31, 2000, there were no fees billed by
Ernst & Young LLP for information technology consulting fees.
During the fiscal year ended December 31, 2000, the aggregate fees billed by
Ernst & Young LLP for professional services other than audit and information
technology consulting fees was $28,890.
The Audit Committee has determined the rendering of all other non-audit
services by Ernst & Young LLP is compatible with maintaining the auditor's
independence.
During the fiscal year ended December 31, 2000, none of the total hours
expended on our financial audit by Ernst & Young LLP were provided by persons
other than Ernst & Young LLP's full-time permanent employees.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 3
7
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
This table outlines the ownership of our Common Stock as of January 12, 2001
by:
- Each director and nominee for director;
- Each executive officer named in the Summary Compensation Table under
"Executive Compensation--Compensation of Executive Officers";
- All directors and executive officers as a group; and
- Every entity that we know beneficially owns more than five percent of our
Common Stock.
BENEFICIAL OWNERSHIP(1)
--------------------------------------
BENEFICIAL OWNER NUMBER OF SHARES PERCENT OF TOTAL(2)
- ---------------- ---------------- -------------------
Citigroup Inc.(3) ...........................
153 Greenwich Street
New York, NY 10043 8,252,133 20.6
Novartis Pharma AG(4) .......................
Lichtstrasse 35
CH-4002, Basel
Switzerland 2,354,150 5.9
Elan International Services, Ltd.(5) ........
102 St. James Court
Flatts, Smiths FL 04
Bermuda 2,176,295 5.3
Stanley T. Crooke(6)......................... 1,324,291 3.3
Christopher F. O. Gabrieli(7)................ 1,269,349 3.2
William R. Miller(8)......................... 62,500 *
B. Lynne Parshall(9)......................... 289,070 *
Mark B. Skaletsky(10)........................ 49,500 *
Joseph H. Wender(11)......................... 73,500 *
C. Frank Bennett(12)......................... 116,586 *
Douglas L. Cole(13).......................... 178,242 *
F. Andrew Dorr(14)........................... 61,854 *
All directors and executive officers as a
group (13 persons)(15)..................... 3,850,008 9.3
- ------------------------
* Less than one percent.
(1) This table is based upon information supplied by officers, directors and
principal stockholders and Schedules 13D and 13G filed with the SEC. Unless
otherwise indicated in the footnotes to this table and subject to community
property laws where applicable, Isis believes that each of the stockholders
named in this table has sole voting and investment power with respect to
the shares indicated as beneficially owned.
(2) Applicable percentages are based on 40,119,564 shares of Common Stock
outstanding on January 12, 2001, adjusted as required by rules promulgated
by the SEC.
(3) Includes 6,696,638 shares held by Salomon Smith Barney Inc., 1,468,650
shares held by SSB Citi Fund Management LLC, 82,715 shares held by Smith
Barney Private Trust Company, and
8
4,130 shares held by Citibank, N.A., all directly or indirectly
wholly-owned subsidiaries of Citigroup Inc.
(4) Includes 38,053 shares of Common Stock held by Novartis Pharmaceuticals
Corporation and 97,097 shares of Common Stock held by Genetic Therapy Inc.
Novartis Pharmaceuticals Corporation and Genetic Therapy Inc. are Delaware
corporations and are directly or indirectly wholly-owned subsidiaries of
Novartis Pharma AG.
(5) Includes 737,951 shares of Common Stock issuable upon conversion of
outstanding convertible notes, and 229,881 shares of Common Stock issuable
upon exercise of outstanding warrants. Also includes 910,844 shares and
297,619 shares of Common Stock held by Elan Pharmaceutical
Investments Ltd. and Elan Pharmaceutical Investments II, Ltd.,
respectively, both affiliates of Elan International Services, Ltd. and both
wholly-owned subsidiaries of Elan Corporation, plc.
(6) Includes 288,516 shares of Common Stock issuable upon exercise of options
held by Dr. Crooke that are exercisable on or before March 13, 2001 and
18,534 shares of Common Stock issuable upon exercise of options held by
Rosanne Crooke, Dr. Crooke's wife, that are exercisable on or before
March 13, 2001. Dr. Crooke disclaims beneficial ownership of the shares of
Common Stock issuable upon exercise of options held by his wife.
(7) Includes 759,566 shares of Common Stock held of record by Bessemer Venture
Partners II ("BVP II"), 329,479 shares of Common Stock held of record by
Bessemer Venture Partners III ("BVP III") and 740 shares of Common Stock
held of record by the Gabrieli Family Foundation ("GFF"). Mr. Gabrieli is a
Manager of Deer II & Co. LLC and of Deer III & Co. LLC, the General
Partners of BVP II and BVP III, respectively, and disclaims beneficial
ownership of the shares of Common Stock held of record by or issuable to
BVP II and BVP III, except to the extent of his respective interests
therein. Mr. Gabrieli is a trustee of GFF and disclaims beneficial
ownership of the shares of Common Stock held of record by or issuable to
GFF. Also includes 53,000 shares of Common Stock issuable upon exercise of
options held by Mr. Gabrieli that are exercisable on or before March 13,
2001.
(8) Includes 20,500 shares of Common Stock issuable upon exercise of options
held by Mr. Miller that are exercisable on or before March 13, 2001.
(9) Includes 269,839 shares of Common Stock issuable upon exercise of options
held by Ms. Parshall that are exercisable on or before March 13, 2001, and
an aggregate of 18,554 shares of Common Stock issuable upon exercise of
options which Ms. Parshall transferred to her daughters that are
exercisable on or before March 13, 2001.
(10) Includes 27,500 shares of Common Stock issuable upon exercise of options
held by Mr. Skaletsky that are exercisable on or before March 13, 2001.
(11) Includes 42,500 shares of Common Stock issuable upon exercise of options
held by Mr. Wender that are exercisable on or before March 13, 2001.
(12) Includes 116,341 shares of Common Stock issuable upon exercise of options
held by Dr. Bennett that are exercisable on or before March 13, 2001.
(13) Includes 175,815 shares of Common Stock issuable upon exercise of options
held by Dr. Cole that are exercisable on or before March 13, 2001.
(14) Includes 61,854 shares of Common Stock issuable upon exercise of options
held by Dr. Dorr that are exercisable on or before March 13, 2001.
(15) Includes an aggregate of 1,467,490 shares issuable upon exercise of
options held by all current directors and executive officers as a group
that are exercisable on or before March 13, 2001.
9
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 (the "1934 Act")
requires Isis' directors and executive officers, and persons who own more than
ten percent of a registered class of our equity securities, to file with the SEC
initial reports of ownership and reports of changes in ownership of Common Stock
and other equity securities of Isis. Officers, directors and greater than ten
percent stockholders are required by SEC regulation to furnish us with copies of
all Section 16(a) forms they file.
To our knowledge, based solely on a review of the copies of such reports
furnished to us and written representations that no other reports were required,
during the fiscal year ended December 31, 2000, all Section 16(a) filing
requirements applicable to our officers, directors and greater than ten percent
beneficial owners were complied with.
EXECUTIVE COMPENSATION
COMPENSATION OF DIRECTORS
We pay our non-employee directors a fee of $15,000 per year. We do not pay
additional compensation for attending Board or Board committee meetings, but we
do reimburse Board members for the expenses they incur to attend the meetings.
For the fiscal year ending December 31, 2000, we paid a total of $82,500 to our
non-employee directors. Dr. Larry Soll resigned in July 2000 and therefore only
received $7,500.
Each non-employee director also receives automatic stock option grants under
our 1992 Non-Employee Directors' Stock Option Plan (the "Directors' Plan"). The
options are non-discretionary and only non-employee directors may receive
options under this plan. On July 1 of each year (or the next business day should
this date fall on a weekend or holiday), each non-employee director receives an
option to purchase 4,000 shares of our Common Stock under the Directors' Plan.
On July 1, 2000, options to purchase an aggregate of 20,000 shares of stock were
granted pursuant to the Directors' Plan. The fair market value of the Common
Stock (and the exercise price of the options) was $14.3125 per share (based on
the closing sales price reported in the Nasdaq National Market on the date of
grant). The options vest over a four year period in equal annual installments.
In addition, upon initial election to the Board, each new non-employee
director receives an automatic grant of an option to purchase 18,000 shares of
our Common Stock pursuant to the Directors' Plan. The exercise price of all
stock option grants under the Directors' Plan is equal to 100% of the fair
market value of the Common Stock on the date of the grant.
On January 6, 2000, we also granted each non-employee director a stock
option under the 2000 Broad Based Equity Incentive Plan (the "2000 Plan") as
retention options. Each non-employee director was granted an option to purchase
10,000 shares of our Common Stock, for an aggregate of 60,000 shares of Common
Stock, pursuant to the 2000 Plan, on that date. The exercise price of the
options was $6.81 per share. The options vest annually over a four year period
in equal annual installments.
10
COMPENSATION OF EXECUTIVE OFFICERS
The following table outlines the compensation paid to or earned by our Chief
Executive Officer and each of our four other highest paid executive officers
whose total annual salary and bonus exceeded $100,000, for the fiscal years
ending December 31, 2000, 1999, and 1998.
SUMMARY COMPENSATION TABLE
LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
---------------------------------- ------------
SECURITIES
OTHER ANNUAL UNDERLYING ALL OTHER
SALARY BONUS COMPENSATION OPTIONS COMPENSATION
NAME AND PRINCIPAL POSITION YEAR ($) ($)(1) ($)(2) (#) ($)
- --------------------------- -------- -------- -------- ------------ ------------ ------------
Stanley T. Crooke................ 2000 400,008 257,605 0 250,000(3) 0
Chairman, CEO and 1999 400,008 0 0 35,000 0
President 1998 361,992 253,400 0 70,000 0
B. Lynne Parshall................ 2000 330,168 172,760 0 170,000(3) 0
Executive Vice President & 1999 307,723 0 0 25,000 0
Chief Financial Officer 1998 265,368 139,315 0 45,000 0
C. Frank Bennett................. 2000 210,187 100,913 0 80,000 0
Vice President, 1999 179,152 0 0 15,000 0
Antisense Research 1998 160,206 57,574 0 14,000 0
Douglas L. Cole.................. 2000 217,300 74,969 0 50,000 0
Vice President, Development 1999 204,472 0 0 10,000 0
Chemistry & Pharmaceutics 1998 202,428 67,357 0 10,000 0
F. Andrew Dorr................... 2000 261,372 109,106 0 118,749(4) 0
Vice President, 1999 238,225 0 0 20,000 0
Chief Medical Officer 1998 198,887 73,833 0 12,000 0
- ------------------------
(1) Bonuses are included here in the years they were earned. Bonuses represent
compensation for achievements and are not necessarily paid in the year they
are earned; i.e., bonuses for 2000 were paid in January 2001.
(2) As permitted by rules promulgated by the SEC, no amounts are shown for any
executive officers where the amounts constitute perquisites and do not
exceed the lesser of 10% of the sum of the aggregate amount in the Salary
and Bonus columns or $50,000.
(3) Options will fully vest on January 2, 2006; provided, however, that the
options will fully vest on January 2, 2002 if certain performance objectives
are met prior to that date. As of January 12, 2001, all of the objectives
had been met.
(4) Includes 10,000 options granted to Dr. Dorr in August in association with
his promotion and 48,749 options issued in a 2 for 1 stock exchange offered
to all non-executive officer employees. At the time of the exchange,
Dr. Dorr was not an executive officer.
STOCK OPTION GRANTS AND EXERCISES
Executive officers are granted stock options under our 1989 Stock Option
Plan and 2000 Plan. As of December 31, 2000, options to purchase a total of
2,045,643 shares of our Common Stock had been granted under the 1989 Stock
Option Plan; options to purchase 2,003,791 shares of our Common Stock had been
granted under the 2000 Plan; and options to purchase 20,000 shares of our Common
Stock had been granted under our Non-Employee Directors Stock Option Plan during
2000.
11
The following tables show certain information regarding options granted to,
exercised by and held at year end December 31, 2000 by each of the executive
officers named in the Summary Compensation Table:
OPTION GRANTS IN LAST FISCAL YEAR
INDIVIDUAL GRANTS
----------------------------------------------- POTENTIAL REALIZABLE
NUMBER OF % OF TOTAL VALUE AT ASSUMED
SECURITIES OPTIONS ANNUAL RATES OF STOCK
UNDERLYING GRANTED TO PRICE APPRECIATION FOR
OPTIONS EMPLOYEES EXERCISE OPTION TERM(3)
GRANTED IN FISCAL PRICE EXPIRATION -----------------------
NAME (#)(1) YEAR(2) ($/SH) DATE 5% ($) 10% ($)
- ---- ---------- ---------- -------- ---------- ---------- ----------
Stanley T. Crooke.............. 250,000(4) 6.2 $ 6.8125 01-05-10 1,070,715 2,713,189
B. Lynne Parshall.............. 170,000(4) 4.2 $ 6.8125 01-05-10 728,086 1,844,969
C. Frank Bennett............... 60,000 1.5 $ 6.8100 01-05-10 257,122 651,315
20,000(5) 0.5 6.2500 12-31-09 78,585 199,133
Douglas L. Cole................ 50,000 1.2 $ 6.8100 01-05-10 214,268 542,762
F. Andrew Dorr................. 48,749(6) 1.2 $ 6.8100 12-31-02 20,679 73,444
60,000 1.5 6.8100 01-05-10 257,122 651,315
10,000(7) 0.2 12.1875 08-15-10 76,620 194,155
- ------------------------
(1) Options granted in 2000 vest over a four-year period: 25% after the first
year and 2.08% per month thereafter except those noted.
(2) Based on options to purchase an aggregate of 4,046,134 shares granted in
2000 under our 1989 Stock Option Plan and our 2000 Plan. This is not
necessarily indicative of the number of options that will be granted in the
future.
(3) The potential realizable value is calculated based on the term of the option
at its time of grant, based on the assumption that the market value of the
underlying stock increases at the stated values, compounded annually.
(4) Reflects options that will fully vest on January 2, 2006; provided, however,
that the options will fully vest on January 2, 2002 if certain performance
objectives are met prior to that date. As of January 12, 2001, all of the
objectives had been met.
(5) Includes 20,000 options granted to Dr. Bennett in January 2000 in connection
with his promotion.
(6) Reflects 48,749 options issued in a 2 for 1 stock exchange offered to all
non-executive officer employees. At the time of the exchange, Dr. Dorr was
not an executive officer.
(7) Includes 10,000 options granted to Dr. Dorr in August in association with
his promotion.
12
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FY-END OPTION VALUES
NUMBER OF VALUE OF
SECURITIES UNEXERCISED
UNDERLYING IN-THE-MONEY
UNEXERCISED OPTIONS AT FISCAL
OPTIONS AT FISCAL YEAR END
YEAR END (#) ($)(2)
SHARES VALUE ----------------- -----------------
ACQUIRED ON REALIZED EXERCISABLE/ EXERCISABLE/
NAME EXERCISE (#) ($)(1) UNEXERCISABLE UNEXERCISABLE
- ---- ------------- ---------- ----------------- -----------------
Stanley T. Crooke.................. 0 0 281,483/287,659 $632,923/$953,125
B. Lynne Parshall.................. 62,335 $1,624,437 283,664/195,564 $459,986/$648,125
C. Frank Bennett................... 3,700 $ 71,906 91,007/91,793 $4,169/$316,400
Douglas L. Cole.................... 0 0 159,804/58,096 $635,738/$190,750
F. Andrew Dorr..................... 4,416 $ 59,600 36,259/110,074 $85,239/$329,639
- ------------------------
(1) Fair market value of our Common Stock on the date of exercise minus the
exercise price.
(2) Fair market value of our Common Stock at December 31, 2000 ($10.625)
multiplied by the applicable number of shares minus the aggregate exercise
price of the options for the number of shares.
EMPLOYMENT AGREEMENTS, TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROL
ARRANGEMENTS
In January 2000, we entered into agreements with certain key employees
pursuant to which we agreed to provide the covered employees with severance
benefits under certain conditions, including Stanley T. Crooke, B. Lynne
Parshall, C. Frank Bennett, Douglas L. Cole and F. Andrew Dorr. In the event
that a covered employee's employment is terminated without "cause," as defined
in the agreement, by Isis on or before December 31, 2001 (the "Severance
Period"), the employee will be eligible to receive a severance payment equal to
a minimum of six months of his or her then current base salary, less payroll
deductions and withholdings.
In the event that the covered employee's employment is terminated by us
during the Severance Period as a result of a reduction of our workforce or the
employee elects to terminate his or her employment with Isis as a result of
substantial change in his or her primary job duties, the severance payment will
be increased to at least nine months of the covered employee's then current base
salary, less payroll deductions and withholdings.
In the event that the covered employee's employment is terminated by Isis
during the Severance Period as a result of a "change in control" as defined in
the agreement, the employee's severance payment will be increased so that he or
she will receive a total of 24 months of his or her then current base salary,
less payroll deductions and withholdings.
13
COMPENSATION COMMITTEE REPORT(1)
The Compensation Committee of the Board of Directors consists of Mark B.
Skaletsky, Chairman, William R. Miller and Joseph H. Wender, none of whom has
ever been an officer or employee of Isis. The Compensation Committee's
responsibilities include:
- Making recommendations concerning executive salaries and incentive
compensation;
- Awarding stock options, bonus stock and rights to purchase restricted
stock under our 1989 Stock Option Plan and the 2001 Broad-Based Equity
Incentive Plan;
- Administering our 2001 Employee Stock Purchase Plan; and
- Determining executive compensation levels and performing other functions
regarding compensation as the Board of Directors requests.
The full Board of Directors reviews the Compensation Committee's
recommendations regarding the compensation of executive officers.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
As noted above, during the fiscal year ended December 31, 2000, our
Compensation Committee was composed of Messrs. Skaletsky, Miller and Wender,
none of which have ever been employees or officers of Isis. None of our
executive officers serves as a member of the board of directors or compensation
committee of any entity that has one or more executive officers serving as a
member of our Board of Directors or Compensation Committee.
EXECUTIVE COMPENSATION
We design our executive compensation programs to attract and retain
executives who can help us meet our business objectives and to motivate them to
enhance long-term stockholder value. The executive officers' annual compensation
consists of three elements: cash salary, a cash incentive bonus and stock option
grants.
To determine fair compensation, the Compensation Committee reviews
historical and current salary, bonus and stock award information for other
comparable companies in similar geographic areas and at similar stages of growth
and development. The group of comparable companies is not necessarily the same
as the companies included in the market indices included in the performance
graph in this Proxy Statement. The Compensation Committee also reviews a variety
of industry surveys throughout the year, which provide additional information
about short and long-term executive compensation. Based in part on this
information, the Compensation Committee generally sets salaries, including that
of our Chief Executive Officer, at levels comparable to competitive companies of
comparable size in similar industries. We structure our management bonus program
around both individual and Company performance. We base the total size of the
cash bonus pool on our success in meeting performance goals for the year,
accounting for changes the Compensation Committee discusses and agrees to during
the course of the year.
We use our stock option program to give management employees a substantial
economic interest in the long-term appreciation of our Common Stock. We grant
existing members of management new options on an annual basis to provide a
continuing financial incentive. The size of the individual annual option grants
is related to the executive's position and performance in the previous year.
- ------------------------
(1) The material in this report is not "soliciting material," is not deemed
filed with the SEC and is not to be incorporated by reference in any filing
of Isis under the Securities Act of 1933, as amended (the "1933 Act"), or
the 1934 Act.
14
The following table shows certain information concerning the repricing of
options received by the Named Executive Officers during the last ten years.
OPTION REPRICING INFORMATION
LENGTH OF
NUMBER OF ORIGINAL
SECURITIES MARKET PRICE OPTION TERM
UNDERLYING OF STOCK AT EXERCISE PRICE NEW REMAINING AT
OPTIONS/SARS TIME OF AT TIME OF EXERCISE DATE OF
REPRICED OR REPRICING OR REPRICING OR PRICE REPRICING OR
NAME DATE AMENDED (#) AMENDMENT ($) AMENDMENT ($) ($) AMENDMENT
- ---- -------- ------------ ------------- -------------- -------- ------------
F. Andrew Dorr ............. 1-1-00 48,749(1) 6.25 (2) 6.81 (2)
Vice President, Chief
Medical Officer
- ------------------------
(1) These shares were issued in connection with a stock option exchange program
offered to all non-executive officer employees. This program was not offered
to executive officers or directors, and Dr. Dorr was not an executive
officer at the time he participated. The options were exchanged at a ratio
of 2 existing option shares for each 1 exchanged option share (option shares
rounded down and each grant calculated individually).
(2) 90,000 options with an exercise price of $18.125 granted on June 1, 1996
would have been fully vested in five months from the date of the exchange;
7,500 options with an exercise price of $18.00 granted on January 1, 1997
would have been fully vested in one year from the date of the exchange. The
remaining terms of the cancelled options were six years and seven years,
respectively.
TAXES
Under Section 162(m) of the Internal Revenue Code of 1986, as amended, we
can only deduct up to $1 million of compensation we pay to certain executive
officers each taxable year. However, we may deduct compensation above
$1 million if it is "performance based compensation" within the meaning of the
Internal Revenue Code. The Compensation Committee has determined that stock
options granted under the 1989 Stock Option Plan with an exercise price at least
equal to the fair market value of our Common Stock on the date of grant will be
treated as performance-based compensation.
ASSESSMENT OF 2000
We set extremely challenging objectives for 2000. In achieving the majority
of those objectives, we made significant progress in the following areas:
- We received $161 million in cash of which approximately $137 million was
from new sources;
- We initiated a collaboration between our Ibis Therapeutics division and
Agouron Pharmaceuticals, Inc., a Pfizer company;
- We completed Phase II clinical trials for ISIS 3521 in non-small cell lung
cancer and achieved positive results. The FDA granted Isis fast track
review status for ISIS 3521 in non-small cell lung cancer and approved the
start of Phase III clinical trials;
- We re-analyzed the Phase IIb results of ISIS 2302 in Crohn's disease using
a population pharmacokinetics analysis and determined sufficient activity
to initiate a new Phase II trial at higher doses;
- We initiated Phase I clinical trials for ISIS 104838, Isis' first second
generation chemistry;
15
- We initiated GeneTrove-TM- collaborations with the R. W. Johnson
Pharmaceutical Research Institute, a member of the Johnson & Johnson
family of companies, and AstraZeneca plc and extended our Abbott
Laboratories, Inc. collaboration to include commercial scale
manufacturing;
- We initiated Phase I/II clinical trials for ISIS 14803 for Hepatitis C;
- We achieved expense reductions of approximately $9 million as a result of
our restructuring plan;
- We identified a drug candidate for Type 2 Diabetics which inhibits the
PTP-lB gene;
- We demonstrated that topically delivered ISIS 2302 effectively inhibits
ICAM-1 in a SCID mouse model for psoriasis; and
- We were issued 167 worldwide patents this year.
COMPENSATION FOR OUR CEO
Dr. Crooke's compensation is determined in accordance with the criteria
described above for all executive officers. The Compensation Committee
recommended that Dr. Crooke receive a salary increase of 12.5%, to $450,000 for
2001. Dr. Crooke did not receive a salary increase in 2000. In January 2001,
Dr. Crooke received a bonus of $257,605 for accomplishments in 2000. In
January 2000, the Committee also approved an option grant of 250,000 shares of
Common Stock for Dr. Crooke, pursuant to our 1989 Stock Option Plan, which will
fully vest on January 2, 2006; provided, however, that the option will fully
vest on January 2, 2002, if certain performance objectives are met as of that
date. As of January 12, 2001, all of the performance objectives had been met.
The stock option grant was made on January 6, 2000, at an exercise price of
$6.8125 per share, the fair market value on the date of grant.
Mark B. Skaletsky, Chairman
William R. Miller
Joseph H. Wender
16
AUDIT COMMITTEE REPORT
The Audit Committee oversees our financial reporting process on behalf of
the Board of Directors. Management has the primary responsibility for the
financial statements and the reporting process, including the systems of
internal controls. In fulfilling its oversight responsibilities, the Audit
Committee reviewed the audited financial statements in our Annual Report on
Form 10-K for the year ended December 31, 2000 with management, including a
discussion of the quality, not just the acceptability, of the accounting
principles, the reasonableness of significant judgments, and the clarity of
disclosures in the financial statements.
The Audit Committee reviewed with our independent auditors, who are
responsible for expressing an opinion on the conformity of our audited financial
statements with generally accepted accounting principles, their judgments as to
the quality, not just the acceptability, of our accounting principles and any
other matters as are required to be discussed with the Audit Committee under
generally accepted auditing standards. In addition, the Audit Committee has
discussed with the independent auditors the auditors' independence from
management and Isis, including the matters in the written disclosures required
by the Independence Standards Board. The Audit Committee received from Ernst &
Young LLP written disclosure and the letter regarding its independence as
required by Independence Standards Board Standard No. 1. The Audit Committee
also discussed with our independent auditors the matters required by the
Statement on Auditing Standards No. 61.
The Audit Committee discussed with our independent auditors the overall
scope and plans for their audit. The Audit Committee meets with the independent
auditors, with and without management present, to discuss the results of their
examinations, their evaluations of our internal controls, and the overall
quality of our financial reporting.
In reliance on the reviews and discussions referred to above, the Audit
Committee recommended to the Board of Directors, and the Board has approved,
that the audited financial statements be included in the Annual Report on
Form 10-K for the year ended December 31, 2000 for filing with the Securities
and Exchange Commission. The Audit Committee and the Board have also
recommended, subject to stockholder approval, the selection of our independent
auditors.
Joseph H. Wender, Audit Committee Chairman
Mark B. Skaletsky, Audit Committee Member
Christopher F. O. Gabrieli, Audit Committee Member
17
PERFORMANCE MEASUREMENT COMPARISON(1)
COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN AMONG
ISIS PHARMACEUTICALS, INC.,
THE NASDAQ COMPOSITE INDEX (TOTAL RETURN) AND
THE AMEX BIOTECH INDEX
EDGAR REPRESENTATION OF DATA POINTS USED IN PRINTED GRAPHIC
DEC-99 DEC-00 DEC-01 DEC-02 DEC-03 DEC-04
Isis Pharmaceuticals Inc. $100 $137 $94 $99 $48 $81
AMEX Biotech Index $100 $108 $121 $138 $293 $474
Nasdaq U.S. $100 $123 $151 $213 $395 $238
SOURCE: GEORGESON SHAREHOLDER COMMUNICATIONS INC.
The above table and chart assume $100 invested on December 31, 1995 in our
Common Stock, the NASDAQ Composite Index (Total Return) and the AMEX Biotech
Index. Total return assumes reinvestment of dividends.
- ------------------------
(1) This Section is not "soliciting material," is not deemed filed with the SEC
and is not to be incorporated by reference in any filing of Isis under the
1933 Act or the 1934 Act.
CERTAIN TRANSACTIONS
In April 1999, Isis and Elan Corporation, plc formed a joint venture to
develop technology for the formulation of oral oligonucleotide drugs. The joint
venture, Orasense, Ltd., is a Bermuda limited company which is currently owned
80.1% by Isis and 19.9% by Elan. Isis and Elan each contributed rights to
certain oral drug delivery technology to the joint venture. In addition, Isis
contributed rights to a proprietary oligonucleotide, which will be the first
candidate for oral formulation by Orasense. Isis and Elan will provide
development and manufacturing services to Orasense and will be entitled to
royalties on any milestone payments and royalties received by Orasense for
development of orally formulated oligonucleotide drugs. If Isis enters into an
agreement with Orasense for oral formulation of any Isis oligonucleotide drug,
Isis will pay Orasense royalties and a portion of certain third party milestone
payments with respect to the drug. In conjunction with this transaction, Isis
sold 910,844 shares of Isis' Common Stock to Elan International Services ("EIS")
for $15,000,000, and issued a warrant to purchase up to 215,000 shares of Isis'
Common Stock at $24 per share. The term of the warrant is five years. Isis also
sold 120,150 shares of Isis' Series A Convertible Preferred Stock to EIS for
$12,015,000. EIS has made available to Isis an $18,400,000 line of credit under
a convertible debt arrangement. Since April 1999, EIS borrowed $8,962,000 under
this convertible debt agreement, which Isis used to provide development funding
to Orasense. For the years ended December 31, 2000 and
18
1999, Isis recorded $5,217,000 and $4,402,000, respectively, in revenue from
Orasense. For the years ended December 31, 2000 and 1999, Isis recorded
$9,702,000, and $7,242,000, respectively as equity in the net loss of Orasense.
In January 2000, Isis and Elan Corporation, plc formed a new joint venture
to develop an antisense drug to treat patients chronically infected with the
Hepatitis C virus (HCV). This new joint venture, HepaSense Ltd., is a Bermuda
limited company which is currently owned 80.1% by Isis and 19.9% by Elan.
HepaSense plans to develop and commercialize this novel therapeutic for HCV,
while investigating delivery of the therapeutic with Elan's proprietary
MEDIPAD-Registered Trademark- Drug Delivery System, a disposable subcutaneous
infusion device. Isis and Elan have each licensed technology to HepaSense. Isis
and Elan will provide development and manufacturing services to HepaSense and
will be entitled to royalties on any milestone payments and royalties received
by HepaSense for development of HCV drugs. In conjunction with this transaction,
Isis sold 298,000 shares of Isis' Common Stock to EIS for $7,500,000, and issued
to EIS a warrant to purchase up to 14,881 shares of Isis' Common Stock at
$50.40 per share. The term of the warrant is five years. Isis also sold
12,015 shares of Isis' Series B Convertible Preferred Stock to EIS for
$12,015,000. EIS has made available to Isis a $12,015,000 line of credit under a
convertible debt arrangement. During the year, Isis borrowed $1,834,000 under
this convertible debt agreement, which Isis used to provide development funding
to HepaSense. For the year ended December 31, 2000, Isis recorded $2,751,000 in
revenue from HepaSense and recorded $6,237,000 as equity in the net loss of
HepaSense.
OTHER MATTERS
The Board of Directors knows of no other matters that will be presented for
consideration at the Annual Meeting. If any other issues are properly brought
before the meeting, we will ask our proxy holders to vote on the matters using
their best judgment.
For further information about Isis Pharmaceuticals, please request a copy of
our Annual Report. The report is the Form 10-K for the year ended December 31,
2000 that we filed with the Securities and Exchange Commission, and is available
free of charge. Please send written requests to:
B. Lynne Parshall, Secretary
Isis Pharmaceuticals, Inc.
2292 Faraday Avenue
Carlsbad, CA 92008
By Order of the Board of Directors
/s/ B. Lynne Parshall
SECRETARY
March 6, 2001
19
EXHIBIT A
CERTIFICATE OF AMENDMENT OF
RESTATED CERTIFICATE OF INCORPORATION OF
ISIS PHARMACEUTICALS, INC.
Isis Pharmaceuticals, Inc., a corporation organized and existing under and
by virtue of the General Corporation Law of the State of Delaware, does hereby
certify:
FIRST: The name of the Corporation is Isis Pharmaceuticals, Inc. (the
"Corporation").
SECOND: The date on which the Corporation's original Certificate of
Incorporation was filed with the Secretary of State of the State of Delaware is
March 25, 1991.
THIRD: The Board of Directors of the Corporation, acting in accordance with
the provisions of Sections 141 and 242 of the General Corporation Law of the
State of Delaware, adopted resolutions at a meeting held on December 8, 2000 to
amend Article V of the Restated Certificate of Incorporation of the Corporation
to read in its entirety as follows:
The Corporation is authorized to issue two classes of shares
designated respectively "Common Stock" and "Preferred Stock." The
total number of shares of all classes of stock which the
Corporation has authority to issue is 115,000,000 shares,
consisting of 100,000,000 shares of Common Stock, each having a
par value of $.001, and 15,000,000 shares of Preferred Stock, each
having a par value of $.001. The Preferred Stock may be issued in
one or more series. The Board of Directors is authorized to fix
the number of shares of any such series of Preferred Stock and to
determine the designation of any such series (a "Preferred Stock
Designation"), subject to (a) such stockholder approvals as may be
provided for herein and (b) the number of shares of Preferred
Stock authorized at that time by this Article V. Subject to such
stockholder approvals as may be provided for herein, the Board of
Directors is further authorized to determine or alter the rights,
preferences, privileges and restrictions granted to or imposed
upon any wholly unissued series of Preferred Stock, and to
increase or decrease (but not below the number of shares of such
series then outstanding) the number of shares of any series of
Preferred Stock. In case the number of shares of any series shall
be so decreased, the shares constituting such decrease shall
resume the status that they had prior to the adoption of the
resolution or amendment originally fixing the number of shares of
such series.
FOURTH: The foregoing amendment was submitted to the stockholders of the
Corporation for their approval and was duly adopted in accordance with the
provisions of Section 242 of the General Corporation Law of the State of
Delaware.
IN WITNESS WHEREOF, Isis Pharmaceuticals, Inc. has caused this Certificate
of Amendment to be signed by its duly authorized officers this day of
, 2001.
By: -----------------------------------------
Stanley T. Crooke
CHAIRMAN OF THE BOARD OF DIRECTORS
AND CHIEF EXECUTIVE OFFICER
20
ISIS PHARMACEUTICALS, INC.
PROXY SOLICITED BY THE BOARD OF DIRECTORS
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 6, 2001
The undersigned hereby appoints STANLEY T. CROOKE and B. LYNNE PARSHALL,
and each of them, as attorneys and proxies of the undersigned, with full
power of substitution, to vote all of the shares of stock of Isis
Pharmaceuticals, Inc. (the "Company") which the undersigned may be entitled
to vote at the Annual Meeting of Stockholders of the Company to be held at
the Company's offices at 2292 Faraday Avenue, Carlsbad, California 92008 on
Friday, April 6, 2001 at 2:30 p.m., and at any and all continuations and
adjournments thereof, with all powers that the undersigned would possess if
personally present, upon and in respect of the following matters and in
accordance with the following instructions, with discretionary authority as
to any and all other matters that may properly come before the meeting.
UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WHEN PROPERLY
EXECUTED WILL BE VOTED FOR ALL NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALS
2 AND 3 AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT. IF SPECIFIC
INSTRUCTIONS ARE INDICATED, THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED
IN ACCORDANCE THEREWITH.
(CONTINUED ON OTHER SIDE)
PLEASE DETACH AND MAIL IN THE ENVELOPE PROVIDED
A /X/ PLEASE MARK YOUR
VOTES AS IN THIS
EXAMPLE
FOR all nominees WITHHOLD
listed at right (except AUTHORITY
as marked to the to vote for all
contrary below) nominees listed at right
Proposal 1: To elect
two directors to / / / /
hold office until
the 2004 Annual Meeting
of Stockholders
To withhold authority to vote
for any nominee(s), write
such nominee(s) name(s) below:
______________________________
______________________________
______________________________
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE NOMINEES FOR DIRECTOR
LISTED BELOW
NOMINEES: Stanley T. Crooke
Mark B. Skaletsky
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSALS 2 AND 3.
FOR AGAINST ABSTAIN
Proposal 2: To approve an amendment to
the Company's Restated Certificate of
Incorporation to increase the authorized / / / / / /
number of shares of common stock from
50,000,000 to 100,000,000 shares.
Proposal 3: To ratify the selection of
Ernst & Young LLP as independent auditors
of the Company for its fiscal year ending / / / / / /
December 31, 2001.
PLEASE VOTE, DATE AND PROMPTLY RETURN THIS PROXY IN THE ENCLOSED RETURN
ENVELOPE WHICH IS POSTAGE PREPAID IF MAILED IN THE UNITED STATES.
SIGNATURE___________________________________ DATE__________________
SIGNATURE___________________________________ DATE__________________
(SIGNATURE IF HELD JOINTLY)
NOTE: Please sign exactly as your name appears hereon. If the stock is
registered in the names of two or more persons, each should sign.
Executors, administrators, trustees, guardians and attorneys-in-fact
should add their titles. If signer is a corporation, please give full
corporate name and have a duly authorized officer sign, stating title.
If signer is a partnership, please sign in partnership name by authorized
person.